<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05036135</url>
  </required_header>
  <id_info>
    <org_study_id>AV-101-002</org_study_id>
    <nct_id>NCT05036135</nct_id>
  </id_info>
  <brief_title>A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)</brief_title>
  <acronym>IMPAHCT</acronym>
  <official_title>IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients With Pulmonary Arterial Hypertension (PAH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aerovate Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aerovate Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      IMPAHCT: Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial is a Phase 2b/Phase&#xD;
      3 study to evaluate the safety and efficacy of AV-101 (dry powder inhaled imatinib) in&#xD;
      patients with Pulmonary Arterial Hypertension (PAH). The Phase 2b part of the study will&#xD;
      assess three doses to establish an optimal dose for the Phase 3 part of the study. The Phase&#xD;
      2b primary endpoint will be the placebo corrected change in pulmonary vascular resistance&#xD;
      (PVR). The Phase 3 primary endpoint will be the placebo corrected change in 6-minute walk&#xD;
      distance (6MWD) after 24 weeks of treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 2b: Change from Baseline in Pulmonary Vascular Resistance (PVR)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 3: Change from Baseline in Six Minute Walk Distance (6MWD)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 2b: Change from Baseline in N-terminal pro B-type natriuretic peptide (NT-proBNP)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2b: Change from Baseline in Six Minute Walk Distance (6MWD)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2b: Incidence of Clinical Worsening</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2b: Proportion of Subjects with Improvement in WHO Functional Class</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2b: Change from Baseline in Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) Lite 2.0 Risk Score</measure>
    <time_frame>24 weeks</time_frame>
    <description>REVEAL Lite 2.0 risk scores range from 1 to 14; a higher score represents higher risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2b: Change from Baseline in Health-Related Quality of Life emPHasis-10 Questionnaire Score</measure>
    <time_frame>24 weeks</time_frame>
    <description>emPHasis-10 questionnaire scores range from 0 - 50; a higher score represents a higher symptom burden</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3: Change from Baseline in NT-proBNP</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3: Time to Clinical Worsening</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3: Proportion of Subjects with Improvement in WHO Functional Class</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3: Change from Baseline in Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) Lite 2.0 Risk Score</measure>
    <time_frame>24 weeks</time_frame>
    <description>REVEAL Lite 2.0 risk scores range from 1 to 14; a higher score represents higher risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3: Change from Baseline in Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire Score</measure>
    <time_frame>24 weeks</time_frame>
    <description>PAH-SYMPACT is a patient reported outcome instrument developed to assess PAH symptoms and impacts</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">462</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Phase 2b low dose AV-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2b medium dose AV-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2b high dose AV-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2b Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 3 dose AV-101 (Optimal dose selected in Phase 2b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 3 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AV-101</intervention_name>
    <description>AV-101 (imatinib) administered via dry powder inhalation</description>
    <arm_group_label>Phase 2b high dose AV-101</arm_group_label>
    <arm_group_label>Phase 2b low dose AV-101</arm_group_label>
    <arm_group_label>Phase 2b medium dose AV-101</arm_group_label>
    <arm_group_label>Phase 3 dose AV-101 (Optimal dose selected in Phase 2b)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered via dry powder inhalation</description>
    <arm_group_label>Phase 2b Placebo</arm_group_label>
    <arm_group_label>Phase 3 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria&#xD;
&#xD;
          -  PAH belonging to one of the subgroups:&#xD;
&#xD;
               1. I/HPAH, PAH-CTD,&#xD;
&#xD;
               2. PAH due to drugs and/or toxins/chemicals (having been in the care of the&#xD;
                  investigator for at least one year with no relapses of drug or toxin/chemical&#xD;
                  abuse),&#xD;
&#xD;
               3. HIV associated or&#xD;
&#xD;
               4. PAH due to repaired congenital heart disease (at least 1 year since repair)&#xD;
&#xD;
          -  World Health Organization (WHO) Functional Class II, III or IV symptoms&#xD;
&#xD;
          -  Stable concomitant background therapy of at least two PAH approved medications&#xD;
&#xD;
          -  Able to walk a distance of at least 100 m but no more than 475 m during the Screening&#xD;
             6-minute walk tests.&#xD;
&#xD;
        Key Exclusion Criteria&#xD;
&#xD;
          -  Pulmonary hypertension (PH) belonging to Groups 2 to 5&#xD;
&#xD;
          -  A history of left-sided heart disease&#xD;
&#xD;
          -  Pregnant or breast-feeding females&#xD;
&#xD;
        Additional criteria may apply, per protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>(888) 373-8110</phone>
    <email>clinicaltrials@aerovatetx.com</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Arterial Hypertension</keyword>
  <keyword>Lungs</keyword>
  <keyword>Pulmonary</keyword>
  <keyword>PAH</keyword>
  <keyword>AV-101</keyword>
  <keyword>imatinib</keyword>
  <keyword>IMPAHCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

